Monocyte Counts and Prostate Cancer Outcomes in White and Black Men: Results from the SEARCH database
Overview
Public Health
Authors
Affiliations
Purpose: Circulating inflammatory markers may predict prostate cancer (PC) outcomes. For example, a recent study showed that higher peripheral blood monocyte counts were associated with aggressive PC in Asian men undergoing radical prostatectomy (RP). Herein, we investigated whether peripheral monocyte count can predict long-term PC outcomes after RP in black and white men.
Methods: We retrospectively reviewed data on 2345 men undergoing RP from 2000 to 2017 at eight Veterans Affairs hospitals. Data on monocyte count within 6 and 12 months prior to surgery were collected. The study outcomes were biochemical recurrence (BCR), castration-resistant PC (CRPC), metastasis, all-cause mortality (ACM), and PC-specific morality (PCSM). Cox-proportional hazard models were used to assess the associations between pre-operative monocyte count and the above-mentioned outcomes accounting for confounders.
Results: Of 2345 RP patients, 972 (41%) were black and 1373 (59%) were white men. In multivariable analyses, we found no associations between monocyte count and BCR among all men (HR: 1.36, 95%CI 0.90-2.07) or when analyses were stratified by race (HR: 1.30, 95%CI 0.69-2.46, in black men; HR:1.33, 95%CI 0.76-02.33, in white men). Likewise, no overall or race-specific associations were found between monocyte count and CRPC, metastases, ACM, and PCSM, all p ≥ 0.15. Results were similar for monocyte count measured at 12 months prior to RP.
Conclusion: In black and white PC patients undergoing RP, peripheral monocyte count was not associated with long-term PC outcomes. Contrary to what was found in Asian populations, monocyte count was not associated with PC outcomes in this study.
NK Cell-Microbiota Interaction Biomarker Strategy: Advancing Prostate Cancer Management.
Fanijavadi S, Hansen T, Zedan A Biomolecules. 2025; 15(2).
PMID: 40001576 PMC: 11852595. DOI: 10.3390/biom15020273.
Immunome profiling in prostate cancer: a guide for clinicians.
San-Jose Manso L, Alfranca A, Moreno-Perez I, Ruiz-Vico M, Velasco C, Toquero P Front Immunol. 2024; 15:1398109.
PMID: 39635522 PMC: 11614818. DOI: 10.3389/fimmu.2024.1398109.
Predictive role of Naples prognostic score for survival in esophageal cancer: A meta-analysis.
Guo H, Wang T Medicine (Baltimore). 2024; 103(21):e38160.
PMID: 38787991 PMC: 11124694. DOI: 10.1097/MD.0000000000038160.
Deep Learning-Based Multi-Omics Integration Robustly Predicts Relapse in Prostate Cancer.
Wei Z, Han D, Zhang C, Wang S, Liu J, Chao F Front Oncol. 2022; 12:893424.
PMID: 35814412 PMC: 9259796. DOI: 10.3389/fonc.2022.893424.